ZA200101290B - Expression and export of angiostatin and endostatin as immunofusins. - Google Patents

Expression and export of angiostatin and endostatin as immunofusins.

Info

Publication number
ZA200101290B
ZA200101290B ZA200101290A ZA200101290A ZA200101290B ZA 200101290 B ZA200101290 B ZA 200101290B ZA 200101290 A ZA200101290 A ZA 200101290A ZA 200101290 A ZA200101290 A ZA 200101290A ZA 200101290 B ZA200101290 B ZA 200101290B
Authority
ZA
South Africa
Prior art keywords
region
endostatin
immunofusins
angiostatin
export
Prior art date
Application number
ZA200101290A
Other languages
English (en)
Inventor
Kin-Ming Lo
Yue Li
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of ZA200101290B publication Critical patent/ZA200101290B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200101290A 1998-08-25 2001-02-15 Expression and export of angiostatin and endostatin as immunofusins. ZA200101290B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9788398P 1998-08-25 1998-08-25

Publications (1)

Publication Number Publication Date
ZA200101290B true ZA200101290B (en) 2002-02-15

Family

ID=22265602

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200101290A ZA200101290B (en) 1998-08-25 2001-02-15 Expression and export of angiostatin and endostatin as immunofusins.

Country Status (20)

Country Link
US (3) US20030139365A1 (https=)
EP (1) EP1107989B1 (https=)
JP (3) JP2002523036A (https=)
CN (2) CN101386651A (https=)
AT (1) ATE462725T1 (https=)
AU (1) AU761027B2 (https=)
BR (1) BR9913331A (https=)
CA (1) CA2339331C (https=)
CZ (1) CZ302303B6 (https=)
DE (1) DE69942207D1 (https=)
DK (1) DK1107989T3 (https=)
ES (1) ES2342239T3 (https=)
HK (1) HK1042503A1 (https=)
HU (1) HUP0103329A3 (https=)
NO (1) NO20010918L (https=)
PL (1) PL202057B1 (https=)
PT (1) PT1107989E (https=)
RU (1) RU2240328C2 (https=)
WO (1) WO2000011033A2 (https=)
ZA (1) ZA200101290B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303401A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
IL131803A0 (en) * 1999-09-08 2001-03-19 Genena Ltd Method for improving the efficiency of cancer gene therapy
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US7160858B2 (en) 2000-09-01 2007-01-09 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
ES2272537T3 (es) * 2000-09-01 2007-05-01 Philadelphia, Health And Education Corporation Metodos y composiciones para inhibir la angiogenesis.
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
CN100543036C (zh) * 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
DE602004015142D1 (de) * 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
JP2005301419A (ja) * 2004-04-07 2005-10-27 Hitachi Ltd ディスクアレイ装置およびそのデータ処理方法
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
RU2303997C2 (ru) * 2005-09-27 2007-08-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US7807409B2 (en) * 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
AT506216B1 (de) 2008-02-13 2009-07-15 Peter Dr Hernuss Zusammensetzung zur aufnahme über mukoses gewebe
RU2372354C1 (ru) * 2008-02-28 2009-11-10 Сергей Викторович Луценко Слитый белок, имеющий активность ингибитора ангиогенеза
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
KR101579318B1 (ko) * 2010-04-29 2015-12-21 엘지전자 주식회사 태양 전지 및 그 제조 방법
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
RU2465283C1 (ru) * 2011-06-27 2012-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвити Рекомбинантный гибридный полипептид, способный ингибировать пролиферацию эндотелиальных клеток человека in vitro, и способ его получения
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
WO2014200312A1 (ko) * 2013-06-14 2014-12-18 주식회사 엘지화학 유기태양전지 및 이의 제조방법
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160126391A1 (en) * 2014-10-31 2016-05-05 Byd Company Limited Solar cell module and manufacturing method thereof
JP7033062B2 (ja) * 2015-10-23 2022-03-09 アポジェニックス アーゲー 一本鎖ｃｄ１３７受容体アゴニストタンパク質
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
CA3002741A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
JP7051697B2 (ja) 2015-12-03 2022-04-11 ハイデルベルク バイオテック ゲーエムベーハー 線維症又は線維症関連疾患を治療及び診断するための手段及び方法
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109824779B (zh) * 2017-11-23 2023-05-26 中山大学 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白
CN112236448B (zh) 2018-04-17 2025-02-11 海德堡生物技术有限公司 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
US20240100134A1 (en) * 2021-01-20 2024-03-28 Monash University Fusion proteins
US20250179209A1 (en) * 2022-03-09 2025-06-05 Immunofyx Anti-cancer n-terminal fc conjugated immunotherapeutics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
CN1305387A (zh) * 1998-04-17 2001-07-25 利思进药品公司 通过共同给予前列腺素抑制剂增强抗体－细胞因子融合蛋白介导的免疫应答
CA2331370A1 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Also Published As

Publication number Publication date
JP2013128490A (ja) 2013-07-04
ATE462725T1 (de) 2010-04-15
DE69942207D1 (de) 2010-05-12
HUP0103329A3 (en) 2003-09-29
WO2000011033A3 (en) 2000-06-22
JP2009273478A (ja) 2009-11-26
ES2342239T3 (es) 2010-07-02
US20070009538A1 (en) 2007-01-11
PL346703A1 (en) 2002-02-25
US8703908B2 (en) 2014-04-22
US20030139365A1 (en) 2003-07-24
HUP0103329A2 (hu) 2001-12-28
US8206718B2 (en) 2012-06-26
CN101386651A (zh) 2009-03-18
US20130165634A1 (en) 2013-06-27
CN1326467A (zh) 2001-12-12
NO20010918D0 (no) 2001-02-23
BR9913331A (pt) 2001-05-15
CN100422332C (zh) 2008-10-01
JP2002523036A (ja) 2002-07-30
EP1107989B1 (en) 2010-03-31
EP1107989A2 (en) 2001-06-20
AU761027B2 (en) 2003-05-29
PL202057B1 (pl) 2009-05-29
CZ2001643A3 (cs) 2002-02-13
NO20010918L (no) 2001-04-19
WO2000011033A2 (en) 2000-03-02
AU5583699A (en) 2000-03-14
RU2240328C2 (ru) 2004-11-20
CA2339331C (en) 2011-03-01
PT1107989E (pt) 2010-07-02
DK1107989T3 (da) 2010-05-25
CZ302303B6 (cs) 2011-02-16
HK1042503A1 (zh) 2002-08-16
CA2339331A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
ZA200101290B (en) Expression and export of angiostatin and endostatin as immunofusins.
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
FR2724182B1 (fr) Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
IL110829A0 (en) Hybrid toxin fragments and toxins comprising them
DE60040225D1 (en) Erythropoietin immunglobulin fusionsproteine
ATE209669T1 (de) Biologisch abbaubare zusammensetzung
GB9610967D0 (en) Specific binding members,materials and methods
WO1998049286A3 (en) Directed evolution of enzymes and antibodies
NO2013009I1 (no) Alipogen tiparvovec
EA200100216A1 (ru) Композиции на основе слитого белка ов и способы их применения
WO1997000319A3 (en) Chimeric leptin fused to immunoglobulin domain and use
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
IL136667A0 (en) Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
AU2130697A (en) Recombinant ribonuclease proteins
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
AU2486900A (en) Rubredoxin fusion proteins, protein expression system and methods
AU5021796A (en) Recombinant human anti-lewis b antibodies
Reboul et al. Characterization of Clq, Cls and Cl̄ Inh synthesized by stimulated human monocytes in vitro
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
EP0863157B8 (de) Anti-Megakaryozyten monoklonaler Antikörper 97A6
AU2173799A (en) Expression of fusion proteins
WO1998024894A3 (de) Pkd1-fragmente mit bindungsregionen für pkd1-spezifische antikörper
AUPP111097A0 (en) Extended recombinant chimeric antibody fragments
CA2245804A1 (en) Recombinant ribonuclease proteins
ZA973029B (en) Expression of recombinant peptides.